title: The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction.
authors: Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL.
authors: Stephen J
authors: SJ
authors: Greene
authors: Mihai
authors: M
authors: Gheorghiade
authors: Barry A
authors: BA
authors: Borlaug
authors: Burkert
authors: B
authors: Pieske
authors: Muthiah
authors: M
authors: Vaduganathan
authors: John C
authors: JC
authors: Burnett
authors: Lothar
authors: L
authors: Roessig
authors: Johannes-Peter
authors: JP
authors: Stasch
authors: Scott D
authors: SD
authors: Solomon
authors: Walter J
authors: WJ
authors: Paulus
authors: Javed
authors: J
authors: Butler
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism*; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D058990:Molecular Targeted Therapy; D015290:Second Messenger Systems / Q000187:drug effects*; D013318:Stroke Volume; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents; D006152:Cyclic GMP
keywords: cGMP; heart failure; phosphodiesterase 5; preserved ejection fraction; soluble guanylate cyclase